Literature DB >> 6886002

"Fibrinogen Tokyo II". An abnormal fibrinogen with an impaired polymerization site on the aligned DD domain of fibrin molecules.

M Matsuda, M Baba, K Morimoto, C Nakamikawa.   

Abstract

A hereditary dysfibrinogenemia associated with defective aggregation of fibrin monomers was found in a 39-yr-old female and in the members of her immediate family, who had all been asymptomatic. The abnormality was probably due to an impaired polymerization site exposed in the DD domain of two adjacent fibrin molecules, because plasmic fragment DD derived from the propositus' cross-linked fibrin bound far less tightly to insolubilized normal fragment E than that from the normal one. Its complementary polymerization site in the E domain of fibrin, which was exposed by thrombin cleavage, and the polymerization site in the D domain of fibrinogen, which was available without activation by thrombin, were both found to be normal. More anodal migration of the abnormal fragment DD than the normal one, as shown by immunoelectrophoresis, seemed to support our concept that the mutation most likely resides in the D domain of the abnormal fibrinogen molecule at or near a region closely related to the polymerization site that is exposed when two fibrin molecules are linearly aligned. The work of others on the polymerization of normal fibrin with different techniques yielded results consistent with our conclusions. We tentatively designate this type of abnormal fibrinogen "fibrinogen Tokyo II," but its possible identity with other abnormalities of fibrinogen reported heretofore is not excluded.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6886002      PMCID: PMC1129270          DOI: 10.1172/JCI111027

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  27 in total

1.  Fibrin-stabilizing factor (factor XIII).

Authors:  C G Curtis; L Lorand
Journal:  Methods Enzymol       Date:  1976       Impact factor: 1.600

Review 2.  Abnormal fibrinogens. A review.

Authors:  D Ménaché
Journal:  Thromb Diath Haemorrh       Date:  1973-06-28

3.  Evidence for localization of polymerization sites in fibrinogen.

Authors:  B J Kudryk; D Collen; K R Woods; B Blombäck
Journal:  J Biol Chem       Date:  1974-05-25       Impact factor: 5.157

4.  High molecular weight derivatives of human fibrinogen produced by plasmin. 3. Their NH2-terminal amino acids and comparison with the "NH2-terminal disulfide knot".

Authors:  V J Marder; A Z Budzyński; H L James
Journal:  J Biol Chem       Date:  1972-08-10       Impact factor: 5.157

5.  Acceleration of fibrin polymerization by calcium ions.

Authors:  M H Boyer; J R Shainoff; O D Ratnoff
Journal:  Blood       Date:  1972-03       Impact factor: 22.113

6.  A rapid method for the purification of bovine thrombin and the inhibition of the purified enzyme wtih phenylmethylsulfonyl fluoride.

Authors:  R L Lundblad
Journal:  Biochemistry       Date:  1971-06-22       Impact factor: 3.162

7.  Plasminogen: purification from human plasma by affinity chromatography.

Authors:  D G Deutsch; E T Mertz
Journal:  Science       Date:  1970-12-04       Impact factor: 47.728

8.  Fibrinogen Detroit - an abnormal fibrinogen with non-functinal NH2-terminal polymerization domain.

Authors:  B Kudryk; B Blombäck; M Blombäck
Journal:  Thromb Res       Date:  1976-07       Impact factor: 3.944

9.  Cross-linking of cold-insoluble globulin by fibrin-stabilizing factor.

Authors:  D F Mosher
Journal:  J Biol Chem       Date:  1975-08-25       Impact factor: 5.157

10.  Fibrinogen Bethesda: a congenital dysfibrinogenemia with delayed fibrinopeptide release.

Authors:  H R Gralnick; H M Givelber; J R Shainoff; J S Finlayson
Journal:  J Clin Invest       Date:  1971-09       Impact factor: 14.808

View more
  5 in total

1.  The role of fibrinogen D domain intermolecular association sites in the polymerization of fibrin and fibrinogen Tokyo II (gamma 275 Arg-->Cys).

Authors:  M W Mosesson; K R Siebenlist; J P DiOrio; M Matsuda; J F Hainfeld; J S Wall
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

Review 2.  Structure and function of human fibrinogen inferred from dysfibrinogens.

Authors:  Michio Matsuda; Teruko Sugo
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

3.  Fibrinogen Lima: a homozygous dysfibrinogen with an A alpha-arginine-141 to serine substitution associated with extra N-glycosylation at A alpha-asparagine-139. Impaired fibrin gel formation but normal fibrin-facilitated plasminogen activation catalyzed by tissue-type plasminogen activator.

Authors:  H Maekawa; K Yamazumi; S Muramatsu; M Kaneko; H Hirata; N Takahashi; C L Arocha-Piñango; S Rodriguez; H Nagy; J L Perez-Requejo
Journal:  J Clin Invest       Date:  1992-07       Impact factor: 14.808

4.  Fibrinogen Osaka IV: a congenital dysfibrinogenemia found in a patient originally reported in relation to surgery, now defined to have an A alpha arginine-16 to histidine substitution.

Authors:  K Yamazumi; S Terukina; M Matsuda; J Kanbayashi; M Sakon; T Tsujinaka
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

5.  A gamma methionine-310 to threonine substitution and consequent N-glycosylation at gamma asparagine-308 identified in a congenital dysfibrinogenemia associated with posttraumatic bleeding, fibrinogen Asahi.

Authors:  K Yamazumi; K Shimura; S Terukina; N Takahashi; M Matsuda
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.